Skip to content

<img width="204" height="84" src="https://www.umoja-biopharma.com/wp-content/uploads/2022/06/Umoja-Biopharma.svg" class="custom-logo" alt="Umoja Biopharma" decoding="async" />

Our Company
Our Science
Our Pipeline
News + Resources
Careers
Contact

Our Company
Our Science
Our Pipeline
News + Resources
Careers
Contact

<img width="204" height="84" src="https://www.umoja-biopharma.com/wp-content/uploads/2022/06/Umoja-Biopharma.svg" class="custom-logo" alt="Umoja Biopharma" decoding="async" />

Our Company
Our Science
Our Pipeline
News + Resources
Careers
Contact

Accessibility
Privacy Policy
Transparency in Coverage
Sitemap

Media

Years when articles were posted

September 26, 2023

Positive early-stage results for in vivo CAR T technology

Drug Discovery World

September 5, 2023

Umoja’s in vivo CAR-T therapy shows positive first signs in primates

Fierce Biotech

September 2, 2023

In Vivo CAR T-Cell Therapeutics With Umoja Biopharma’s Dr Andrew Scharenberg

Cell & Gene: The Podcast

August 9, 2023

Next-Gen Immunotherapies for Cancer, Andrew Scharenberg, Co-founder & CEO, Umoja Biopharma

Biotech2050 Podcast

July 21, 2023

How is an increased focus on patient-centric concerns influencing the way that you work?

Pharma’s Almanac

Our Company
Our Science
Manufacturing
Partnerships
Our Pipeline
Careers

Press Releases
In The Media
Blog
White Papers
Presentations

1616 Eastlake Ave E.
Suite 550
Seattle, WA 98102
info@umoja-biopharma.com

Accessibility
Privacy Policy
Transparency in Coverage
Sitemap

© 2023 Umoja Biopharma. All rights reserved.